Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

H. Ballentine Carter

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer'. Together they form a unique fingerprint.